Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) issued its quarterly earnings results on Tuesday. The company reported ($0.59) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.59), MarketWatch Earnings reports.
Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down 4.10% during midday trading on Tuesday, hitting $14.26. 57,585 shares of the stock traded hands. Aquinox Pharmaceuticals has a 52 week low of $8.36 and a 52 week high of $19.97. The firm’s market capitalization is $334.01 million. The company’s 50-day moving average is $14.56 and its 200 day moving average is $15.60.
WARNING: This piece of content was reported by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another site, it was illegally copied and reposted in violation of US and international copyright & trademark law. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2017/08/08/aquinox-pharmaceuticals-inc-aqxp-announces-earnings-results-misses-expectations-by-0-08-eps.html.
Several equities research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday. Zacks Investment Research lowered shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, July 11th. ValuEngine upgraded shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Cantor Fitzgerald set a $28.00 price target on shares of Aquinox Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, May 9th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $22.50.
In related news, insider David Main sold 15,625 shares of the stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $13.26, for a total transaction of $207,187.50. Following the transaction, the insider now owns 77,530 shares in the company, valued at $1,028,047.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 2.70% of the stock is owned by corporate insiders.
Hedge funds have recently made changes to their positions in the stock. Investment Centers of America Inc. acquired a new stake in shares of Aquinox Pharmaceuticals during the first quarter worth approximately $172,000. Archon Partners LLC boosted its stake in shares of Aquinox Pharmaceuticals by 44.0% in the second quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock worth $253,000 after buying an additional 5,500 shares in the last quarter. Alps Advisors Inc. boosted its stake in shares of Aquinox Pharmaceuticals by 4.7% in the second quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock worth $297,000 after buying an additional 939 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Aquinox Pharmaceuticals by 16.5% in the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock worth $327,000 after buying an additional 3,299 shares in the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Aquinox Pharmaceuticals by 10.0% in the first quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock worth $2,028,000 after buying an additional 11,035 shares in the last quarter. 98.32% of the stock is owned by institutional investors and hedge funds.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.